The development of advanced therapies is a complex process that goes far beyond the initial scientific discovery. Transforming an idea into a medicinal product capable of reaching patients requires planning, coordination and a deep understanding of both regulatory and technical requirements.

In this context, defining a clear strategy from the earliest stages of development becomes essential.

Drawing on experience gained across research, regulatory and manufacturing environments, several common themes emerge in successful advanced therapy development programmes. Early planning, clear development pathways and a structured approach can have a significant impact on long-term success.

The importance of strategy from the start

When a research group believes it may have a potential advanced therapy medicinal product, one of the first critical steps is to define an appropriate development strategy.

This involves not only evaluating the therapeutic potential but also understanding what type of data will be required to support it from a regulatory perspective. In early stages, this translates into properly designing preclinical studies so that the data generated can be used in later phases of development.

To achieve this, it is highly valuable to rely on teams with experience in advanced therapy development, or to connect with other research groups that have already gone through similar processes. Learning from previous experience helps avoid common pitfalls and optimise both time and resources.

Planning and coordination as key success factors

One of the main risks in advanced therapy development is the lack of proper planning. When projects progress without a clear strategy, efforts can become fragmented, leading to inefficiencies and delays.

A structured and stepwise approach is therefore essential. This includes defining priorities, understanding what needs to be done first, and ensuring that each step builds on the previous one.

It is also important to narrow the initial scope of the project. Attempting to address multiple indications from the outset can hinder progress. Focusing on a specific objective in early stages allows for more robust results that can support further development.

The role of preclinical development

The preclinical phase is a critical stage in the development of advanced therapies. At this stage, key aspects must be demonstrated, including:

• Safety
• Biodistribution
• Toxicity

These elements are well defined from a regulatory standpoint and provide a clear framework for researchers.

Careful planning of preclinical studies ensures that the data generated will support progression into clinical phases.

Managing biological uncertainty

Advanced therapies involve a high degree of biological complexity. This is particularly evident in autologous therapies, where variability between patients is inherently high.

As a result, development must account for a wide range of potential outcomes and define acceptable limits within which the product can be considered safe and effective.

Establishing appropriate characterisation parameters and understanding variability across different cell sources are key steps in managing this uncertainty.

Product characterisation: an increasing challenge

As advanced therapies become more complex, so do the requirements for product characterisation.

Regulatory authorities require a detailed understanding of the product, including its components, properties and behaviour. This can become particularly challenging in more complex products, such as those based on secretomes or other multifactorial biological systems.

If not anticipated early in development, these requirements can become a significant barrier to progress.

Why do many therapies not reach the market?

Despite the high level of innovation in the field, only a limited number of advanced therapies ultimately reach the market.

This is due to a combination of factors, including: technical complexity, regulatory requirements, challenges in product characterisation and, in many cases, insufficient planning in early stages

What can we learn from successful developments?

Therapies that successfully progress from early research to clinical use share a common characteristic: a structured and well-organised development process.

These projects have managed to align each stage (from early research through clinical development) ensuring that the data generated at each step supports the next.

The development of advanced therapies is inherently complex and long-term, making careful planning and execution essential.

A key recommendation

For research groups working on potential therapeutic candidates, one recommendation stands out: seek support early in the development process.

Access to experience (whether through collaborators or specialised teams) helps structure development, anticipate challenges and move forward more effectively within a highly regulated environment.